Antimicrobial resistance (AMR) is one of the most pressing global health challenges today. It arises when bacteria, viruses, fungi, and parasites evolve to resist the effects of medications that once effectively treated infections.
The growing prevalence of AMR – which, based on 2021 data, was found to be responsible for more deaths than HIV/AIDS, malaria or most cancers – threatens to nullify decades of medical advancements, leading to higher mortality rates, prolonged hospital stays, and increased healthcare costs. But AMR is not just a health crisis. The potential macroeconomic consequences, and the financial consequences of AMR for companies, are far-reaching.
While addressing AMR will require a coordinated global effort involving governments, healthcare providers, and pharmaceutical companies, investors also have a critical role to play.
To learn more, download the full article written by Rachel Crossley, our Head of Stewardship Europe, and Alexander Bernhardt, our Global Head of Sustainability Research.
